SEC filings and other documents

Explore the latest company documents and SEC filings from the company, including Forms 10-K, 10-Q, 8-K, and other key disclosures. Evaluate financial performance and operational updates to make more informed decisions.

2026

Earnings, Q2 FY2026

Aug 19, 2026

Q2 2026 revenue up 39%, gross profit positive, net loss narrowed, U.S. sales led growth.

Earnings, Q1 FY2026

May 15, 2026

Q1 2026 saw 85% revenue growth, positive gross profit, and major debt reduction amid NYSE compliance issues.

2025

Earnings, Q4 FY2025

Mar 25, 2026

Q1 2026 PAPZIMEOS sales expected to exceed $18M, reflecting rapid adoption and broad coverage.

Earnings, Q3 FY2025

Nov 14, 2025

IPO completed, revenue up 35% YoY, and new patent strengthens growth prospects.

Earnings, Q2 FY2025

Sep 12, 2025

IPO raised $17M as net loss widened to $12.3M on $2.74M revenue; ongoing losses expected.

H.C. Wainwright 27th Annual Global Investment Conference

Sep 10, 2025

Market leader advances total artificial heart tech, targeting global growth and next-gen innovation.

Picard Medical, Inc.

SEC filings and other documents